Skip to content

To explore the intervention effect of Xiaoyu Xiezhuo Yin on chronic cyclosporin nephropathy in patients with aplastic anemia based on autophagy and ACE2-Ang(1-7)-Mas axis

To explore the intervention effect of Xiaoyu Xiezhuo Yin on chronic cyclosporin nephropathy in patients with aplastic anemia based on autophagy and ACE2-Ang(1-7)-Mas axis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004187
Enrollment
Unknown
Registered
2020-09-30
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cyclosporine nephropathy

Interventions

Control group:Conventional treatment
therapy group:Conventional treatment+traditional Chinese medicine
The AA control group:none

Sponsors

The First Affiliated Hospital of ZheJiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for aplastic anemia; 2. Meet the diagnostic criteria of chronic cyclosporin A nephropathy; 3. Meet the diagnostic criteria of TCM syndromes; 4. Patients are between 18-75 years old; 5. Aplastic anemia, infection, acidosis, electrolyte disturbance, high blood pressure, etc. are well controlled; 6. No other organ failure.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic or allergic to the known ingredients of the study drug; 2. Patients diagnosed with acute kidney injury, and patients undergoing hemodialysis and peritoneal dialysis; 3. Patients with severe damage to heart, liver, lungs and other organs, or patients with malignant tumors, active tuberculosis and other wasting diseases; 4. Those with gastrointestinal bleeding, or those who need to take other types of Chinese medicine during the test period; 5. Those who do not cooperate with treatment; 6. Those with recent history of surgery; 7. Pregnant and lactating women; 8. Researchers believe that it is inappropriate to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
LC3-II;SOD;Beclin-1;Ang(1-7);ACE;p62;MDA;Klotho;TGF- beta 1;Ang II;Serum creatinine;ACE2;

Secondary

MeasureTime frame
Blood urea nitrogen;CysC;Uric acid;ACR;

Countries

China

Contacts

Public ContactKeDa Lu

The First Affiliated Hospital of ZheJiang Chinese Medical University

lukedaq@126.com+86 13757175879

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026